Multiple sclerosis (MS) is the most common neurologic disease in young adults. Spasticity is one of its most disabling symptoms, with botulinum toxin A type A (BoNT-A) being one of the treatments of choice for this symptom.
OBJECTIVE:
We assessed the response to abobotulinumtoxinA in improving walking ability and fatigue in patients with spastic paraparesis caused by MS.
METHODS:
We performed a real-world, multicenter, prospective, open-label low-intervention trial in 84 patients with MS and spastic paraparesis of the lower limbs infiltrated with abobotulinumtoxinA (LINITOX study). The response of spasticity, walking ability and fatigue is analyzed in 4 cycles of ultrasound-guided injection in the lower limbs.
RESULTS:
The patients improved their walking ability by an average of 11.34% meters measured with 6-Minute Walk Test (6MWT), and decreased the percentage of fatigue by 6.86% (4.66 percentage points less), in the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) 4 weeks after abobotulinumtoxinA injection, both values are statistically significant. This improvement seems to persist over time, throughout the cycles.
CONCLUSION:
We found improved walking ability and less fatigue in patients with MS-related spastic paresis of the lower limbs after injection of abobotulinumtoxinA.
Amatya,B., Khan,F., GaleaM. (2019). Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev, 1(1), CD012732https://doi.org/10.1002/14651858.CD012732.pub2.
3.
Arriaza Gómez,M. J. (2023). Resultados de salud, funcionalidad y fatiga de un programa estructurado de reentrenamiento al esfuerzo en pacientes con esclerosis múltiple. [Tesis doctoral]. Universidad Autónoma de Madrid. https://repositorio.uam.es/handle/10486/706699.
4.
Cameron,M. H., Nilsagard,Y. (2018). Balance, gait, and falls in multiple sclerosis, Handb Clin Neurol159, 237–250.
5.
Cerda,A. L. (2014). Manejo del trastorno de marcha del adulto mayor, 25(2), 265–275.
6.
Chan,A., Silván,C. V. (2022). Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap. Neurodegener Dis Manag, 12(3), 141–154.
7.
Cioncoloni,D., Taddei,S., Bielli,S., Annunziata,P., Mazzocchio,R. (2014). Meaningful improvement in walking performance after Botulinum Neurotoxin A (BoNT-A) in chronic spastic patients. Parente R, editor. NeuroRehabilitation34(1), 185–192.
8.
Comi,G., Solari,A., Leocani,L., Centonze,D., Otero-Romero,S., the Italian Consensus Group on treatment of spasticity in multiple sclerosis.
(2020). Italian consensus on treatment of spasticity in multiple sclerosis. Eur J Neurol, 27(3), 445–453.
9.
Correa-Diaz,E. P., Jácome-Sánchez,E., Torres-Herrán,G., Masabanda-Campaña,L., Baño-Jiménez,G., Altamirano-Brito,M. J., Santos-Saltos,D., Caiza-Zambrano,F., Ortega Heredia,A., Paredes González,V., García Castillo,M. A., Guillén-López,F. (2018). Prognostic Factors In Multiple Sclerosis Rev. Ecuat. Neurol, 27(1).
10.
Dashtipour,K., Chen,J. J., Walker,H. W., Lee,M. Y. (2016). Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb Spasticity. Medicine (Baltimore), 95(2), e2468.
11.
Demetrios,M., Khan,F., Turner-Stokes,L., Brand,C., McSweeney,S. (2013). Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity. Cochrane Database Syst Rev6, CD009689.
12.
Dressler,D., Bhidayasiri,R., Bohlega,S., Chahidi,A., Chung,T. M., Ebke,M., Jacinto,L. J., Kaji,R., Koçer,S., Kanovsky,P., Micheli,F., Orlova,O., Paus,S., Pirtosek,Z., Relja,M., Rosales,R. L., Sagástegui-Rodríguez,J. A., Schoenle,P. W., Shahidi,G. A., Timerbaeva,S., Walter,U., Saberi,F. A. (2017). Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force, J Neurol, 264(1), 112–120.
Ergul,M., Nodehi Moghadam,A., Soh,R. (2022). The effectiveness of interventions targeting spasticity on functional clinical outcomes in patients with multiple sclerosis: a systematic review of clinical trials. European Journal of Physiotherapy, 24(1), 21–29.
15.
Esquenazi,A., Delgado,M. R., Hauser,R. A., Picaut,P., Foster,K., Lysandropoulos,A., Gracies,J. M. (2020). Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport ®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies, Front Neurol, 11, 576117.
16.
Esquenazi,A., Bavikatte,G., Bandari,D. S., Jost,W. H., Munin,M. C., Tang,S. F. T., Largent,J., Adams,A. M., Zuzek,A., Francisco,G. E. (2021). Long-term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity. PM R13(10), 1079–1093.
Flachenecker,P., Henze,T., Zettl,U. K. (2014). Spasticity in patients with multiple sclerosis – clinical characteristics, treatment and quality of life. Acta Neurol Scand, 129(3), 154–162.
19.
Fu,X., Wang,Y., Wang,C., Wu,H., Li,J., Li,M., Ma,Q., Yang,W. (2018). A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. Clin Rehabil, 32(6), 713–721.
20.
GBD 2016 Multiple Sclerosis Collaborators.
(2019). Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol, 18, 269–285.
21.
Goldman,M. D., Marrie,R. A., Cohen,J. A. (2008). Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler, 14(3), 383–390.
Hobart,J. C., Riazi,A., Lamping,D. L., Fitzpatrick,R., Thompson,A. J. (2003). Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology, 14(60), 31–6.
26.
Kuo,C. L., Hu,G. C. (2018). Post-stroke Spasticity: A Review of Epidemiology, Pathophysiology, and Treatments. International Journal of Gerontology, 12(4), 280–284.
27.
Leocani,L., Colombo,B., Comi,G. (2008). Physiopathology of fatigue in multiple sclerosis. Neurol Sci, (Suppl 2), S241–243.
Miguens, X., Cordero, C., De Miguel, C. (2023) Toxina botulínica en Rehabilitación. Guía de práctica clínica. Artes Gráficas Rupem.
30.
Motl,R. W., McAuley,E., Snook,E. M., Gliottoni,R. C. (2009). Physical activity and quality of life in multiple sclerosis: intermediary roles of disability, fatigue, mood, pain, self-efficacy and social support. Psychol Health Med, 14(1), 111–124.
Ojardias,E., Ollier,E., Lafaie,L., Celarier,T., Giraux,P., Bertoletti,L. (2022). Time course response after single injection of botulinum toxin to treat spasticity after stroke: Systematic review with pharmacodynamic model-based meta-analysis. Ann Phys Rehabil Med, 65(3), 101579.
33.
Otero-Romero,S., Sastre-Garriga,J., Comi,G., Hartung,H. P., Soelberg Sørensen,P., Thompson,A. J., Vermersch,P., Gold,R. (2016). Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler, 22(11), 1386–1396.
34.
Paoloni,M., Giovannelli,M., Mangone,M., Leonardi,L., Tavernese,E., Di Pangrazio,E., Bernetti,A., Snatilli,V., Pozzilli,C. (2013). Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial. Clin Rehabil, 27(9), 803–812.
35.
Thrower,B., Newsome,S. D., Hendin,B., Danese,S., Patterson,J., Chinnapongse,R. (2024). Recognition, Description, and Variability of Spasticity in Individuals With Multiple Sclerosis and Potential Barriers to Clinician-Patient Dialogue: Results From SEEN-MSS, a Large-Scale, Self-Reported Survey. Int J MS Care, 26(2), 75–80.
36.
Trompetto,C., Marinelli,L., Mori,L., Puce,L., Pelosin,E., Serrati,C., Fattapposta,F., Rinalduzzi,S., Abbruzzese,G., Currà,A. (2017). Do flexible inter-injection intervals improve the effects of botulinum toxin A treatment in reducing impairment and disability in patients with spasticity?Med. Hypotheses, 102, 28–32.
37.
Turner-Stokes,L., Jacinto,J., Fheodoroff,K., Brashear,A., Maisonobe,P., Lysandropoulos,A., Ashford,S. (2021). Upper Limb International Spasticity-III (ULIS-III) study group. Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III Study. J Rehabil Med, 53(1), jrm00133.
38.
Vickrey,B. G., Hays,R. D., Harooni,R., Myers,L. W., Ellison,G. W. (1995). A health-related quality of life measure for multiple sclerosis. Qual Life Res, 4(3), 187–206.
39.
Walton,C., King,R., Rechtman,L., Kaye,W., Leray,E., Marrie,R. A., Robertson,N., La Rocca,N., Uitdehaag,B., van der Mei,I., Wallin,M., Helme,A., Angood Napier,C., Rijke,N., Baneke,P. (2020). Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler, 26(14), 1816–1821.
